Drugs / AVAXIM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03917654 | Apr 2019 → Jul 2021 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00313950 | Sep 2006 → Dec 2009 | hepatitis A virus infection, measles, mumps infectious disease, rubella | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVAXIM | “Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children” NCT00313950 ↗ |
| Modality | Vaccine | “Hepatitis A Vaccine Inactivated” NCT03917654 ↗ |